{
    "Orphapacket": {
        "ORPHApacketId": "91127",
        "creationDate": "2023-12-06 11:51:54",
        "version": "1.3.29 / 4.1.7 [2023-08-02] (orientdb version)",
        "copyright": "Orphanet (c) 2023",
        "ORPHAcode": "91127",
        "Label": "Adenovirus infection in immunocompromised patients",
        "PURL": "http://www.orpha.net/ORDO/Orphanet_91127",
        "DisorderType": {
            "value": "Particular clinical situation in a disease or syndrome",
            "PURL": "http://www.orpha.net/ORDO/Orphanet_377793"
        },
        "TextSection": {
            "TextSectionType": "Definition",
            "Contents": "A rare viral disease characterized by invasive and/or disseminated adenovirus infection in immunocompromised patients either acquired <i>de novo</i> or arising from reactivation of persistent latent infection. The clinical picture comprises a wide range of manifestations including pneumonia colitis hepatitis hemorrhagic cystitis tubulointerstitial nephritis encephalitis and disseminated disease among others. Severity varies with age and immune status and life-threatening courses may occur."
        },
        "Parents": [
            {
                "Parent": [
                    {
                        "ORPHAcode": "163585",
                        "Label": "Rare viral disease"
                    }
                ]
            }
        ],
        "Prevalences": {
            "Prevalence": [
                {
                    "Source": "European Medicines Agency 2003[INST]",
                    "PrevalenceType": "Point prevalence",
                    "PrevalenceQualification": "Value and class",
                    "PrevalenceClass": "1-5 / 10 000",
                    "ValMoy": "18.0",
                    "PrevalenceGeographic": "Europe"
                }
            ]
        },
        "TypeOfInheritances": {
            "TypeOfInheritance": [
                {
                    "value": "Not applicable"
                }
            ]
        }
    }
}